Precisely. So, for as nutty as some people thin
Post# of 15624
So, for as nutty as some people think my dream was of $50/share as a buyout... It's really NOT that far fetched if you really sit, think, and realize the GWPH comparison is relevant. Doesn't feel relevant yet, but we WILL BE.
Once we have Cream(s) on the market and the Sublingual Tablet is available (either direct sales or licensing deal)... We have more going for us than GWPH.
Again, GWPH currently trading at $3.27+ Billion and Goldman Sachs says they're worth $8.8 Billion...
Our current share structure means $50/share = $7.2 Billion. Anyone: Tell me WHY that's unrealistic given the circumstances/assumptions and facts I've laid out.